A significant increase in heart rate was noted in this SRM, as has previously been reported in people living with T2DM.24 Heart rate increase with tirzepatide was reportedly dose-dependent and higher than other GLP-1 receptor agonists, and the reason remains to be determined.25 Hence, it would be a good clinical practice to avoid the use of tirzepatide in people with tachyarrhythmias, which again tends to be more common in people with obesity. This evidence concerns the gene GLP1R and obesity disorder.